BD 141975 - PowerLoc Max Safety Infusion Set, 19G x 0.75", 25/PK (Continental US Only)

BD 141975 - PowerLoc Max Safety Infusion Set, 19G x 0.75", 25/PK (Continental US Only)

The BD 141975 PowerLoc Max Safety Infusion Set is a power-injectable port-access device designed for accessing compatible surgically implanted vascular ports. The set features a 19-gauge non-coring needle with a 0.75-inch length and is configured without a Y-injection site, providing a direct fluid pathway for compatible infusion therapy, blood sampling, and diagnostic imaging procedures.

The PowerLoc Max platform is designed for administration of compatible fluids and medications, blood specimen collection, implanted port flushing, and power injection through appropriately rated vascular-access systems. The 19-gauge configuration provides a larger fluid pathway suitable for applications requiring higher flow capability.

The 0.75-inch needle length is intended for implanted ports positioned relatively close to the skin surface. Correct needle-length selection helps support complete septum access, stable positioning, secure dressing application, and appropriate patient comfort.

This configuration uses approximately 8-inch tubing and has an approximate priming volume of 0.3 mL. Because the set does not include a Y-injection site, it provides a streamlined direct pathway without an integrated secondary medication or fluid-access point.

The PowerLoc Max design incorporates a stable, padded needle base with a compact wingless footprint. The low-profile design supports dressing application, access-site care, and patient comfort while minimizing unnecessary bulk over the implanted port.

An integrated single-step safety mechanism is housed within the plastic needle base. During deaccessing, the needle is withdrawn through the base, where the mechanism covers the needle point and locks it into a protected position to help reduce accidental needlestick exposure during removal, transport, and disposal.

BD 141975 corresponds to manufacturer catalog number 0141975 and is commercially supplied 25 sets per case.

Key Benefits

• 19-gauge non-coring needle supports access to compatible surgically implanted vascular ports.
• 0.75-inch needle length accommodates appropriately positioned superficial implanted ports.
• Larger 19-gauge fluid pathway supports applications requiring higher flow capability.
• Power-injectable design supports compatible contrast-enhanced diagnostic imaging procedures.
• Maximum power-injection flow rate up to 5 mL per second when the complete vascular-access system is appropriately rated.
• Configuration without a Y-injection site provides a direct and streamlined fluid pathway.
• Approximately 8-inch tubing provides practical working length for port-access procedures.
• Approximate 0.3 mL priming volume supports fluid-management planning.
• Non-coring needle design supports repeated access to compatible implanted port septa when used correctly.
• Stable needle base supports comfort and secure dressing application.
• Non-absorbent padded base is designed to improve patient comfort.
• Compact footprint minimizes unnecessary bulk at the implanted port access site.
• Wingless design supports site care and dressing management.
• Rotating hub helps clinicians position tubing during dressing and therapy management.
• Dual-lumen port compatibility supports appropriate simultaneous infusion applications.
• Single-step safety activation helps simplify needle protection during deaccessing.
• Safety mechanism covers and locks the needle point after withdrawal.
• Audible and visual indications help confirm safety-device activation.
• 25-per-case packaging supports routine hospital, oncology, infusion, and imaging inventory management.

Compatibility and Applications

The BD 141975 PowerLoc Max Safety Infusion Set is intended for use with compatible surgically implanted vascular-access ports designed to accept non-coring port-access needles.

Potential clinical applications include chemotherapy administration, antibiotic therapy, hydration, parenteral nutrition, blood product administration, long-term infusion therapy, blood specimen collection, implanted port flushing, and compatible contrast-media injection during diagnostic imaging procedures.

The 19-gauge configuration may be selected when higher flow capability is required and the implanted port and complete fluid pathway are compatible with a larger-gauge access needle. Selection should consider prescribed therapy, medication or fluid characteristics, required flow rate, implanted port specifications, imaging requirements, and professional clinical judgment.

The 0.75-inch needle length is generally appropriate for implanted ports positioned relatively close to the skin surface. A needle that is too short may not completely access the port septum, while unnecessary additional needle length may affect stability, securement, dressing placement, and patient comfort.

Because BD 141975 does not include a Y-injection site, it provides a direct fluid pathway without an integrated secondary access point. This configuration may be appropriate when the planned therapy uses a primary connection and does not require secondary medication or fluid administration through a Y-site.

The PowerLoc Max platform is compatible with appropriate dual-lumen implanted port applications. Exact compatibility should be confirmed with the implanted port model and the planned therapy before use.

For power injection, the implanted port, PowerLoc Max needle, tubing, connectors, extension components, and every other component within the complete vascular-access pathway must be appropriately rated for the intended procedure. The lowest-rated component determines the maximum permitted pressure and flow rate.

Usage Guidelines

The BD 141975 should be used only by healthcare professionals trained and authorized to access surgically implanted vascular ports. Current manufacturer instructions, aseptic technique, institutional procedures, and implanted port instructions should be followed throughout the procedure.

• Confirm the patient's identity, prescribed therapy, implanted port type, and power-injection status when applicable.
• Assess the location and depth of the implanted port before selecting the 0.75-inch needle.
• Verify that the 19-gauge configuration is appropriate for the intended therapy or imaging procedure.
• Confirm that a configuration without a Y-injection site meets the planned clinical workflow.
• Inspect the package for damage, punctures, moisture, contamination, or compromised integrity.
• Prepare the implanted port site using appropriate skin-antisepsis and sterile-access procedures.
• Prime the complete fluid pathway with an approved solution before port access.
• Remove air completely from the tubing before connection to the implanted vascular-access system.
• Position the rotating hub and tubing as needed before final dressing application.
• Stabilize the implanted port and insert the non-coring needle perpendicular to the septum using an approved technique.
• Advance the needle carefully until appropriate access to the port reservoir is achieved.
• Verify correct needle placement according to institutional protocol, including aspiration for blood return when clinically appropriate.
• Flush the implanted port according to current manufacturer instructions and facility policy.
• Secure the PowerLoc Max base and tubing to minimize pulling, twisting, pressure, or displacement.
• Apply an appropriate sterile dressing while maintaining access-site assessment capability.
• Monitor the site for pain, swelling, redness, leakage, displacement, or other abnormalities throughout therapy.
• Confirm power-injection eligibility before connecting the system to a power injector.
• Do not exceed 5 mL per second or the lower operating limit of any component within the complete vascular-access system.
• After therapy, flush and lock the implanted port according to the prescribed protocol.
• Stabilize the implanted port while withdrawing the needle through the PowerLoc Max base.
• Confirm that the safety mechanism has covered and locked the needle point before further handling.
• Dispose of the used device immediately in an approved sharps container.

Stop the procedure and assess the vascular-access system if unexpected resistance occurs during flushing, expected blood return cannot be obtained, the patient experiences unusual discomfort, or swelling, leakage, displacement, or another abnormality develops at the implanted port site.

Certifications and Safety Standards

The BD 141975 PowerLoc Max Safety Infusion Set is intended for professional medical use within established vascular-access, infusion-therapy, diagnostic imaging, infection-prevention, and occupational safety programs.

The PowerLoc Max safety mechanism is located within the plastic needle base. During appropriate deaccessing, withdrawal of the needle through the base activates the mechanism, which covers the needle point and locks it into the base.

This single-step safety design is intended to help reduce accidental needlestick injuries and potential exposure to bloodborne pathogens during needle removal, transport, and disposal.

Audible and visual indications help the clinician confirm that the safety mechanism has activated. Safety-device functionality does not replace appropriate sharps precautions, personal protective equipment, clinician training, or immediate disposal in an approved sharps container.

The non-coring port-access needle should be selected according to patient anatomy, implanted port depth, prescribed therapy, required flow characteristics, and current manufacturer instructions.

Healthcare organizations should review current manufacturer documentation for applicable FDA status, UDI information, sterilization method, material composition, natural rubber latex information, DEHP information, shelf life, pressure limitations, warnings, precautions, contraindications, and other product-specific regulatory requirements.

Comparison with Competitors

Compared with conventional implanted port needles without integrated safety technology, the PowerLoc Max incorporates a single-step mechanism designed to cover and lock the needle point during deaccessing, helping reduce accidental sharps exposure.

Compared with PowerLoc Max configurations containing a Y-injection site, BD 141975 provides a direct fluid pathway without an integrated secondary access point. This may simplify the tubing configuration when secondary access through a Y-site is not required.

Compared with standard PowerLoc safety infusion sets, the PowerLoc Max platform features a smaller footprint, stable wingless base, non-absorbent comfort pad, and rotating hub designed to support patient comfort and dressing management.

Compared with non-power-injectable port-access needles, BD 141975 supports compatible power-injection procedures at flow rates up to 5 mL per second when every component of the complete vascular-access system is appropriately rated.

Compared with 20-gauge and 22-gauge PowerLoc Max configurations, the 19-gauge needle provides a larger fluid pathway. The 19-gauge and 20-gauge PowerLoc Max configurations support power injection up to 5 mL per second, while compatible 22-gauge configurations are rated for lower maximum flow.

Compared with 1-inch and 1.5-inch access needles, the 0.75-inch configuration provides a lower access profile for implanted ports located closer to the skin surface.

Alternative safety infusion sets may vary in gauge, needle length, Y-site configuration, power-injection capability, tubing design, priming volume, safety mechanism, base design, and package quantity. BD 141975 combines a 19-gauge, 0.75-inch non-coring needle with a compact padded wingless base, rotating hub, direct no-Y-site configuration, integrated safety lockout, and power-injection capability up to 5 mL per second.

Typical User Profile and Application Scenarios

The BD 141975 PowerLoc Max Safety Infusion Set is intended for trained healthcare professionals responsible for accessing and managing surgically implanted vascular ports. Typical users include infusion nurses, oncology nurses, radiology nurses, vascular-access specialists, physicians, advanced practice clinicians, and other qualified healthcare personnel.

Common use environments include hospitals, oncology centers, outpatient infusion clinics, diagnostic imaging departments, ambulatory treatment centers, specialty practices, and other healthcare facilities where implanted vascular ports are routinely accessed.

The product may be selected for patients whose implanted port can be appropriately accessed with a 0.75-inch needle and whose prescribed therapy or diagnostic procedure is compatible with a 19-gauge access device.

Typical applications may include chemotherapy administration, antibiotic infusion, hydration, parenteral nutrition, blood product administration, blood specimen collection, routine implanted port maintenance, and compatible contrast-enhanced imaging procedures.

The no-Y-site configuration is particularly relevant for clinical workflows using a direct primary infusion connection that do not require an integrated secondary medication or fluid-access point.

Best Practices for Use and Maintenance

The BD 141975 is intended for professional implanted port-access procedures. Best practices focus on correct product selection, sterile preparation, accurate needle-length assessment, access-site management, power-injection verification, safety activation, and sharps disposal.

• Verify BD 141975 or manufacturer catalog number 0141975 before opening the package.
• Confirm the 19-gauge size, 0.75-inch needle length, and configuration without a Y-injection site.
• Inspect packaging integrity and expiration information before use.
• Assess patient tissue depth and implanted port position before selecting the needle length.
• Confirm that the prescribed therapy and flow requirements are appropriate for a 19-gauge port-access device.
• Use strict aseptic technique throughout preparation, priming, insertion, connection, dressing, and deaccessing.
• Prime the complete fluid pathway before implanted port access.
• Consider the approximately 0.3 mL priming volume when precise fluid management is clinically important.
• Use the rotating hub to position tubing appropriately before securing the dressing.
• Maintain the padded base in a stable position to minimize unnecessary movement at the access site.
• Monitor the implanted port site and tubing connections throughout therapy.
• Verify that the complete vascular-access system is power injectable before any power-injection procedure.
• Do not exceed 5 mL per second or the lowest pressure or flow limitation of any component within the complete system.
• Do not bend, cut, modify, repair, or otherwise alter the infusion set.
• Follow current manufacturer instructions regarding single-use handling and disposal.
• Confirm complete safety lockout immediately following needle withdrawal.
• Place the protected device directly into an approved sharps container.

Regulatory and Safety Information

The BD 141975 PowerLoc Max Safety Infusion Set should be used only by appropriately trained healthcare professionals and only for applications consistent with current manufacturer labeling, implanted port instructions, professional clinical judgment, and institutional policy.

BD identifies manufacturer catalog number 0141975 as the PowerLoc Max Power-Injectable Infusion Set without Y-Injection Site, 19G x 0.75-inch, with a maximum flow rate of 5 mL per second.

Before use, verify the product identity, 19-gauge size, 0.75-inch needle length, no-Y-site configuration, package integrity, expiration date, and compatibility with the implanted vascular port.

The set should not be used for power injection unless the implanted port and every component within the complete fluid pathway are specifically rated for the intended procedure. Permitted pressure, flow rate, contrast-media characteristics, and other operating conditions must be confirmed before use.

The lowest-rated component within the complete vascular-access system determines the actual maximum allowable operating limit, even though the PowerLoc Max 19-gauge configuration is rated up to 5 mL per second.

Incorrect needle-length selection, incomplete septum access, excessive pressure, needle displacement, or improper securement may contribute to infiltration, extravasation, leakage, tissue injury, implanted port damage, interrupted therapy, or other complications.

Because BD 141975 does not include a Y-injection site, it does not provide an integrated secondary access point within the tubing. Clinical teams should confirm that a direct fluid pathway meets the requirements of the planned therapy.

The integrated safety mechanism should be fully engaged according to current manufacturer instructions after port deaccessing. The used device remains a contaminated sharp and should be discarded immediately in an approved sharps container.

BD lists manufacturer SKU 0141975 as 25 units per shelfpack with a minimum order quantity of one shelfpack, while CIA Medical lists the commercial configuration as 25 per case. Purchasing personnel should confirm current availability, selling unit, storage requirements, and ordering information before procurement.

How to Order

Select the BD 141975 - PowerLoc Max Safety Infusion Set, 19G x 0.75" and add it to your cart. Complete checkout with your preferred shipping and payment options. For bulk orders, quotes, or further assistance, contact CIA Medical customer service at (312)275-5850 or use the contact form on this page.